Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667404 · ClinicalTrials.gov registry record · Phase 2
Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study
A Phase 2 study of Parkinson Disease and Dietary Modification, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03667404: Active Phase 2 study of Parkinson Disease and Dietary Modification, sponsored by Northwestern University.
NCT03667404 is a Phase 2 study of Parkinson Disease and Dietary Modification that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 30 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03667404, a Phase 2 study of Parkinson Disease and Dietary Modification, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability of a dietary fiber, resistant maltodextrin, in people with Parkinson's disease. It will also evaluate the fiber's effect on the gut microbiome and potential effects on motor function and non-motor functions. Half of the participants will receive resistant maltodextrin and the other half will receive a control substance, maltodextrin.
Primary Outcome
Adverse event frequency and severity based on diary reports, phone calls, and in-person assessments.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Resistant maltodextrin
- DIETARY_SUPPLEMENT maltodextrin
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-11-06 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT03667404 still lists
NCT03667404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Resistant maltodextrin is the first listed.
NCT03667404 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03667404 about?
NCT03667404 is a clinical study titled "Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study". This study will evaluate the safety and tolerability of a dietary fiber, resistant maltodextrin, in people with Parkinson's disease. It will also evaluate the fiber's effect on the gut microbiome and potential effects on motor function and non-motor functions. Half of the participants will receive r...
What is the current status of trial NCT03667404?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-11-06. Estimated completion is 2026-03-31.
What conditions does trial NCT03667404 study?
This clinical trial studies the following conditions: Parkinson Disease, Dietary Modification, Intestinal Bacteria Flora Disturbance.
What interventions are being tested in trial NCT03667404?
The interventions under investigation include: Resistant maltodextrin (DIETARY_SUPPLEMENT), maltodextrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03667404?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03667404 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03667404's enrollment target sits among peer trials
30 209th of 297 higher than 80 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI